EUVIMEDEUVIMED entdecken
Open Access

Response Monitoring in Metastatic Breast Cancer: A Prospective Study Comparing 18 F-FDG PET/CT with Conventional CT

Marianne Vogsen, Frederik Harbo, Nick M Jakobsen, Henriette J Nissen, Sara E Dahlsgaard-Wallenius, Oke Gerke, Jeanette D Jensen, Jon T Asmussen, Anne Marie B Jylling, Poul-Erik Braad, Werner Vach, Marianne Ewertz und 1 weitere

Journal of Nuclear Medicine · 2023-03 · 64 (3) · 355-361

DOI: 10.2967/jnumed.121.263358 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 07.10.2022. Verfasst von Marianne Vogsen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Odense University Hospital, Odense, Denmark; marianne.vogsen@rsyd.dk. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Breast Neoplasms. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to compare contrast-enhanced CT (CE-CT) and 18F-FDG PET/CT for response monitoring in metastatic breast cancer using the standardized response evaluation criteria RECIST 1.1 and PERCIST. The objective was to examine whether progressive disease was detected systematically earlier by one of the modalities.

Methods

Women with biopsy-verified metastatic breast cancer were enrolled prospectively and monitored using combined CE-CT and 18F-FDG PET/CT every 9-12 wk to evaluate response to first-line treatment. CE-CT scans and RECIST 1.1 were used for clinical decision-making without accessing the 18F-FDG PET/CT scans. At study completion, 18F-FDG PET/CT scans were unmasked and assessed according to PERCIST. Visual assessment was used if response criteria could not be applied. The modality-specific time to progression was defined as the time from the baseline scan until the first scan demonstrating progression. Paired comparative analyses for CE-CT versus 18F-FDG PET/CT were applied, and the primary endpoint was earlier detection of progression by one modality. Secondary endpoints were time to detection of progression, response categorization, visualization of changes in response over time, and measurable disease according to RECIST and PERCIST.

Results

In total, 87 women were evaluable, with a median of 6 (1-11) follow-up scans. Progression was detected first by 18F-FDG PET/CT in 43 (49.4%) of 87 patients and first by CE-CT in 1 (1.15%) of 87 patients (P < 0.0001). Excluding patients without progression (n = 32), progression was seen first on 18F-FDG PET/CT in 78.2% (43/55) of patients. The median time from detection of progression by 18F-FDG PET/CT to that of CE-CT was 6 mo (95% CI, 4.3-6.4 mo). At baseline, 76 (87.4%) of 87 patients had measurable disease according to PERCIST and 51 (58.6%) of 87 patients had measurable disease according to RECIST 1.1. Moreover, 18F-FDG PET/CT provided improved visualization of changes in response over time, as seen in the graphical abstract.

Conclusion

Disease progression was detected earlier by 18F-FDG PET/CT than by CE-CT in most patients, with a potentially clinically relevant median 6-mo delay for CE-CT. More patients had measurable disease according to PERCIST than according to RECIST 1.1. The magnitude of the final benefit for patients is a perspective for future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyBreast NeoplasmsHumansFemaleFluorodeoxyglucose F18Prospective StudiesTreatment OutcomeRadiopharmaceuticalsTomography, X-Ray Computed

Stichwörter der Autor:innen

18F-FDG PET/CTCE-CTPERCISTmetastatic breast cancerresponse monitoring

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Oncology, Odense University Hospital, Odense, Denmark; marianne.vogsen@rsyd.dk.
  • Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.
  • Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Odense Patient Data Explorative Network (OPEN), Odense University Hospital, Odense, Denmark.
  • Centre for Personalized Response Monitoring in Oncology (PREMIO), Odense University Hospital, Odense, Denmark.
  • Department of Radiology, Odense University Hospital, Odense, Denmark.

Zitieren

APA

Vogsen, M., Harbo, F., Jakobsen, N. M., Nissen, H. J., Dahlsgaard-Wallenius, S. E., Gerke, O., Jensen, J. D., Asmussen, J. T., Jylling, A. M. B., Braad, P. E., Vach, W., Ewertz, M., & Hildebrandt, M. G. (2023). Response Monitoring in Metastatic Breast Cancer: A Prospective Study Comparing 18 F-FDG PET/CT with Conventional CT. Journal of Nuclear Medicine, 64(3), 355-361. https://doi.org/10.2967/jnumed.121.263358

Vancouver

Vogsen M, Harbo F, Jakobsen NM, Nissen HJ, Dahlsgaard-Wallenius SE, Gerke O, et al. Response Monitoring in Metastatic Breast Cancer: A Prospective Study Comparing 18 F-FDG PET/CT with Conventional CT. Journal of Nuclear Medicine. 2023;64(3):355-361. doi:10.2967/jnumed.121.263358

BibTeX
@article{Vogsen2023,
  author = {Vogsen, Marianne and Harbo, Frederik and Jakobsen, Nick M and Nissen, Henriette J and Dahlsgaard-Wallenius, Sara E and Gerke, Oke and Jensen, Jeanette D and Asmussen, Jon T and Jylling, Anne Marie B and Braad, Poul-Erik and Vach, Werner and Ewertz, Marianne and Hildebrandt, Malene G},
  title = {Response Monitoring in Metastatic Breast Cancer: A Prospective Study Comparing 18 F-FDG PET/CT with Conventional CT},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {3},
  pages = {355--361},
  doi = {10.2967/jnumed.121.263358}
}
Kostenlos starten →